to Capture Biotech

Making an impact

That is exactly what drives us. Our goal is to help people! We want our work to help reduce suffering and save lives.

The problem

Even today, there are still diseases for which drug treatment is inadequate or not possible at all. Some of these diseases lead to pathologically increased levels of C-Reactive Protein (CRP). This elevated CRP level is often associated with a poor prognosis.

The C-Reactive Protein (CRP) is a component of the innate immune system. In healthy people, the CRP level is normally below 5 mg/l, but can rise to values > 500 mg/l within 24 to 48 hours, e.g. in severe inflammatory diseases.

In myocardial infarction, the prognosis of patients with a sharp rise in CRP is worse than that of patients with a slight rise in CRP. As early as 2006, it was shown in an animal model that a high CRP level leads to an enlarged infarct area.

This effect was also observed in humans in the CAMI1 study. There was a significant correlation between infarct size and CRP increase in the control group (Ries et al. 2021). In patients with a CRP increase > 0.6 mg/L/h, CRP apheresis was able to reduce the infarct size by 26 %. The positive effect of CRP apheresis was still detectable after several months (Skarabis et al. 2022).

An elevated CRP level is also associated with a poor prognosis for COVID-19.

The removal of CRP from blood plasma therefore has the potential to contribute to the improvement of patient health in both diseases described (Buerke et al. 2022).

A possible solution

Capture Biotech has set itself the goal of changing this. With the help of therapeutic apheresis, a new treatment option will be created.

In the treatment of inflammatory diseases with pathologically elevated CRP levels, the CRP should be specifically removed from the patient's blood so that the harmful effects can be reduced or at best even prevented.